Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 5,053,700	$ 6,168,754
Restricted cash		231,838
Accounts receivable, net	2,760,884	1,986,663
Inventories, net	1,649,230	1,414,600
Loans to customer and supplier	2,963,158	2,892,868
Other receivables	738,730	483,884
Prepayments	6,472,651	9,029,524
Other current assets	30,050	132,746
Deferred tax assets	27,775	27,042
Total current assets	19,696,178	22,367,919
Property, plant and equipment, net	6,339,399	4,813,232
Construction in progress	1,627,652	295,248
Intangible asset, net	1,146,189	1,238,025
Other non-current assets		134,736
Total assets	28,809,418	28,849,160
Current liabilities:
Accounts payable	640,777	646,649
Advance from customers	99,410	128,321
Other payables and accrued liabilities	901,797	942,793
Income tax payable	1,944,216	1,842,139
Convertible notes, net	7,509,232	7,267,677
Current portion of long-term borrowings	1,139,676	1,268,106
Total current liabilities	12,235,108	12,095,685
Advance from government grant	129,990	37,948
Long-term borrowings	732,649	792,567
Total liabilities	13,097,747	12,926,200
Commitments and contingencies
EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 13,324,083 issued and outstanding as of September 30, 2013 and December 31, 2012	13,324	13,324
Additional paid-in capital	12,220,181	12,220,181
Retained earnings	1,625,488	2,485,736
Statutory reserve	373,406	373,406
Accumulated other comprehensive income	1,323,686	658,870
Total Tanke Biosciences Corporation stockholders' equity	15,556,085	15,751,517
Non-controlling interest	155,586	171,443
Total Equity	15,711,671	15,922,960
Total Liabilities and Equity	$ 28,809,418	$ 28,849,160